Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03352466 · ClinicalTrials.gov registry record · Phase 1
NasoShield Study of Safety and Immunogenicity
A Phase 1 study, sponsored by Altimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
NCT03352466: Completed Phase 1 study, sponsored by Altimmune.
NCT03352466 is a Phase 1 study that has completed, run by Altimmune. The registered enrollment target is 145 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (142% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03352466, a Phase 1 study, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
Study Summary
This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety and immunogenicity of NasoShield in healthy adults 18 to 49 years of age.
Primary Outcome
Subjects will record solicited local and systemic events for 14 days after each dose
Interventions
- OTHER Placebo
- BIOLOGICAL BioThrax
- BIOLOGICAL NasoShield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2018-01-18 |
| Est. Completion | 2019-05-13 |
| Phase | Phase 1 |
What the finished NCT03352466 record still lists
NCT03352466 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (142% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03352466 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03352466 about?
NCT03352466 is a clinical study titled "NasoShield Study of Safety and Immunogenicity". This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety and immunogenicity of NasoShield in healthy adults 18 to 49 years of age.
What is the current status of trial NCT03352466?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2018-01-18. Estimated completion is 2019-05-13.
What interventions are being tested in trial NCT03352466?
The interventions under investigation include: Placebo (OTHER), BioThrax (BIOLOGICAL), NasoShield (BIOLOGICAL).
Who is sponsoring clinical trial NCT03352466?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03352466's enrollment target sits among peer trials
145 391st of 2000 higher than 1,607 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI